Efficacy of Almonertinib Versus Osimertinib as the First-Line Treatment for Non-Small Cell Lung Cancer With EGFR L858R Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study [0.03%]
艾美替尼和奥希替尼一线治疗EGFR L858R突变非小细胞肺癌的疗效对比及预后分析：回顾性队列研究
Xiujing Yao,Ruyue Li,Xue Dong et al.
Xiujing Yao et al.
Objectives: Epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitors show less efficacy against the EGFR L858R mutation than EGFR 19del, but no current head-to-head clinical trials have been performed c...
Comparative Study
Cancer medicine. 2025 Dec;14(23):e71422. DOI:10.1002/cam4.71422 2025
Identifying Patterns of Late Effects With Latent Class Analysis Among Adolescent and Young Adult Thyroid Cancer Survivors in California and Utah [0.03%]
加州和犹他州青少年及年轻成人甲状腺癌幸存者后遗症的潜在类别分析
Judy Y Ou,Theresa Keegan,Qian W Li et al.
Judy Y Ou et al.
Introduction: Thyroid cancer is one of the most common cancers in adolescents and young adults (AYA, 15 to 39 years), with an excellent 5-year survival of 98%. However, treatments for thyroid cancer such as radioactive io...
A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors [0.03%]
菲美匹诺特治疗复发和难治性实体瘤和中枢神经系统肿瘤的I期临床试验
David S Shulman,Kieuhoa T Vo,Frank M Balis et al.
David S Shulman et al.
Background: Fimepinostat, an oral dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), has shown activity in preclinical models of Myc-driven pediatric malignancies. This...
Clinical Trial
Cancer medicine. 2025 Dec;14(23):e71417. DOI:10.1002/cam4.71417 2025
Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma [0.03%]
免疫检查点抑制剂单药治疗复发和/或转移性鼻腔和副鼻窦鳞状细胞癌患者的疗效
Alexander Lein,Thorsten Fuereder,Manuel Stoeth et al.
Alexander Lein et al.
Introduction: Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy with limited data on effective treatment modalities in the recurrent and/or metastatic (r/m) setting. While immune checkpoint inhibitors (ICIs) ...
Multicenter Study
Cancer medicine. 2025 Dec;14(23):e71391. DOI:10.1002/cam4.71391 2025
"I Missed My Other Oncologist": Established Relationships as Barriers and Facilitators to Accessing CAR-T and Autologous Transplantation [0.03%]
“我想见的是我的另一名肿瘤科医生”——既有的医患关系对患者接受CAR-T和自体移植治疗的影响与促进作用
Zachary A K Frosch,Clark Meshack,Caitlin Meeker et al.
Zachary A K Frosch et al.
Background: Autologous stem cell transplantation (ASCT) and chimeric antigen receptor T-cell therapy (CAR-T) can provide significant clinical benefit, but are not equally available to all patients. Oncologist continuity a...
Histologic Response to Induction Chemotherapy in High-Risk Neuroblastoma [0.03%]
高危型神经母细胞瘤诱导化疗的组织病理学反应
Monica Pomaville,Pei-Chi Kao,Antonio Perez-Atayde et al.
Monica Pomaville et al.
Introduction: Tumor histology at diagnosis is used in conjunction with other prognostic features to risk stratify patients with neuroblastoma and to assign therapy regimens. In patients with high-risk disease, adjustment ...
Sustainment of Tobacco Use Treatment Programs Across National Cancer Institute-Designated Cancer Centers [0.03%]
全美癌症研究所指定的癌症中心对烟草使用治疗项目的维持与发展状况调查研究
Ramzi G Salloum,Magda Montague,Mara Minion et al.
Ramzi G Salloum et al.
Background: Though tobacco use treatment (TUT) after a cancer diagnosis can improve cancer treatment outcomes and survival, delivery of evidence-based TUT remains underutilized in cancer care. The National Cancer Institut...
JMT103 versus Non-Denosumab or Denosumab Treatment in Chinese Patients with Unresectable or Surgically Challenging Giant Cell Tumor of Bone: A Propensity Score-Matched Comparison [0.03%]
中国非骨盆部位复发/难治性骨巨细胞瘤患者的JMT103与地舒单抗或非地舒单抗治疗比较：倾向性评分匹配分析
Hairong Xu,Yong Zhou,Feng Wei et al.
Hairong Xu et al.
Background: Giant cell tumors of bone (GCTB) are RANK/RANK-ligand positive, progressive osteolytic tumors. There was no medical treatment for GCTB based on efficacy and safety data from Chinese patients. A single-arm, pha...
Observational Study
Cancer medicine. 2025 Nov;14(22):e71340. DOI:10.1002/cam4.71340 2025
COVID-19 Infection Before or After Colorectal Cancer Diagnosis Is an Independent Predictor of Mortality and Treatment Delays Compared to Patients Who Never Tested Positive [0.03%]
与从未检测呈阳性的患者相比，结直肠癌诊断前或诊断后感染新冠肺炎是独立的死亡率和治疗延迟预测指标
Imran Qureshi,Steven Rella,Aasma Shaukat
Imran Qureshi
Background: Given COVID-19's emergence as a new entity and colorectal cancer's (CRC) rising incidence in certain populations, we conducted this retrospective cohort study to determine the link between COVID-19 and the mor...
Wenying Zeng,Yinhui Yang,Wanlian Li et al.
Wenying Zeng et al.
Objective: Pancreatic cancer (PC) is one of the common malignant tumors in gastrointestinal tract. The roles of CERKL in PC are unknown. Methods: ...